Ibuprofen vs. acetaminophen for acute mild-to-moderate pain management: A systematic review and meta-analysis of safety with a focus on paediatric populations

IF 3 3区 医学 Q2 PHARMACOLOGY & PHARMACY
British journal of clinical pharmacology Pub Date : 2026-09-28 Epub Date: 2026-07-14 DOI:10.1002/bcp.70693
Gian Luigi Marseglia, Paola Giovanna Marchisio, Gregorio Paolo Milani, Michele Miraglia del Giudice, Irene Schiavetti, Giorgio Ciprandi
{"title":"Ibuprofen vs. acetaminophen for acute mild-to-moderate pain management: A systematic review and meta-analysis of safety with a focus on paediatric populations","authors":"Gian Luigi Marseglia,&nbsp;Paola Giovanna Marchisio,&nbsp;Gregorio Paolo Milani,&nbsp;Michele Miraglia del Giudice,&nbsp;Irene Schiavetti,&nbsp;Giorgio Ciprandi","doi":"10.1002/bcp.70693","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aims</h3>\n \n <p>The purpose of this study is to compare the safety of ibuprofen and acetaminophen (paracetamol) for acute mild-to-moderate pain in children and adolescents through a systematic review and meta-analysis.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>PubMed, Scopus and Web of Science were searched from inception to May 2026 for randomized controlled trials (RCTs) in patients aged 0–18 years that reported safety outcomes. RCTs enrolling adult or mixed-age populations in acute pain settings were also considered eligible when paediatric-relevant safety data could be extracted. The review was conducted and reported in accordance with the PRISMA 2020 statement. Primary outcomes were total adverse events (AEs), gastrointestinal, renal, hepatic and bleeding events. The risk of bias was assessed using RoB 2. Random-effects meta-analyses were expressed as risk ratios (RR) with 95% confidence intervals (CI).</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Fifteen studies (2847 patients) were included across postoperative pain, musculoskeletal trauma, orthodontic pain and emergency department settings, with follow-up ranging from single-dose assessments to 12 months. Three studies, including 937 participants, contributed to the primary meta-analysis of any adverse event. Ibuprofen was not associated with a statistically significant difference in the risk of any adverse event compared with acetaminophen (RR 0.80, 95% CI 0.36–1.79; <i>I</i><sup>2</sup> = 2.9%). No serious renal or hepatic adverse events were reported.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Available RCT evidence did not show a clear difference in short-term safety between ibuprofen and acetaminophen in paediatric and acute pain populations; however, the certainty of the evidence is limited. Patient factors and clinical context should guide drug choice. Larger RCTs with standardized safety reporting are needed.</p>\n </section>\n </div>","PeriodicalId":9251,"journal":{"name":"British journal of clinical pharmacology","volume":"92 10","pages":"3277-3287"},"PeriodicalIF":3.0000,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British journal of clinical pharmacology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/bcp.70693","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/7/14 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Aims

The purpose of this study is to compare the safety of ibuprofen and acetaminophen (paracetamol) for acute mild-to-moderate pain in children and adolescents through a systematic review and meta-analysis.

Methods

PubMed, Scopus and Web of Science were searched from inception to May 2026 for randomized controlled trials (RCTs) in patients aged 0–18 years that reported safety outcomes. RCTs enrolling adult or mixed-age populations in acute pain settings were also considered eligible when paediatric-relevant safety data could be extracted. The review was conducted and reported in accordance with the PRISMA 2020 statement. Primary outcomes were total adverse events (AEs), gastrointestinal, renal, hepatic and bleeding events. The risk of bias was assessed using RoB 2. Random-effects meta-analyses were expressed as risk ratios (RR) with 95% confidence intervals (CI).

Results

Fifteen studies (2847 patients) were included across postoperative pain, musculoskeletal trauma, orthodontic pain and emergency department settings, with follow-up ranging from single-dose assessments to 12 months. Three studies, including 937 participants, contributed to the primary meta-analysis of any adverse event. Ibuprofen was not associated with a statistically significant difference in the risk of any adverse event compared with acetaminophen (RR 0.80, 95% CI 0.36–1.79; I2 = 2.9%). No serious renal or hepatic adverse events were reported.

Conclusions

Available RCT evidence did not show a clear difference in short-term safety between ibuprofen and acetaminophen in paediatric and acute pain populations; however, the certainty of the evidence is limited. Patient factors and clinical context should guide drug choice. Larger RCTs with standardized safety reporting are needed.

布洛芬与对乙酰氨基酚治疗急性轻中度疼痛:一项以儿科人群为重点的安全性系统评价和荟萃分析。
目的:本研究的目的是通过系统回顾和荟萃分析,比较布洛芬和对乙酰氨基酚(扑热息痛)治疗儿童和青少年急性轻中度疼痛的安全性。方法:检索PubMed、Scopus和Web of Science从成立到2026年5月,0-18岁患者中报告安全性结果的随机对照试验(rct)。当可以提取儿科相关的安全性数据时,纳入急性疼痛设置的成人或混合年龄人群的随机对照试验也被认为是合格的。该审查是根据PRISMA 2020声明进行和报告的。主要结局是总不良事件(ae)、胃肠道、肾脏、肝脏和出血事件。偏倚风险采用RoB 2进行评估。随机效应荟萃分析以95%置信区间(CI)的风险比(RR)表示。结果:15项研究(2847例患者)纳入,涉及术后疼痛、肌肉骨骼创伤、正畸疼痛和急诊科设置,随访时间从单剂量评估到12个月。三项研究,包括937名参与者,对任何不良事件进行了初步荟萃分析。与对乙酰氨基酚相比,布洛芬与任何不良事件的风险无统计学差异(RR 0.80, 95% CI 0.36-1.79; I2 = 2.9%)。没有严重的肾脏或肝脏不良事件的报道。结论:现有的随机对照试验证据未显示布洛芬和对乙酰氨基酚在儿科和急性疼痛人群中的短期安全性有明显差异;然而,证据的确定性是有限的。患者因素和临床情况应指导药物选择。需要更大规模的随机对照试验和标准化的安全报告。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.30
自引率
8.80%
发文量
419
审稿时长
1 months
期刊介绍: Published on behalf of the British Pharmacological Society, the British Journal of Clinical Pharmacology features papers and reports on all aspects of drug action in humans: review articles, mini review articles, original papers, commentaries, editorials and letters. The Journal enjoys a wide readership, bridging the gap between the medical profession, clinical research and the pharmaceutical industry. It also publishes research on new methods, new drugs and new approaches to treatment. The Journal is recognised as one of the leading publications in its field. It is online only, publishes open access research through its OnlineOpen programme and is published monthly.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书